Acute Myeloid Leukemia (AML) Market Report Overview

The acute myeloid leukemia (AML) market in the eight major markets (8MM: the US, France, Germany, Italy, Spain, the UK, Japan, and China) was $2.3 billion in 2022. Steady growth is anticipated at a CAGR of more than 4% throughout the forecast period as the number of AML patients continues to climb and new therapies arrive in the 8MM.

For more details visit: https://www.globaldata.com/store/report/acute-myeloid-leukemia-market-opportunity-analysis/